{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:46Z","timestamp":1779084466602,"version":"3.51.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BA 2851\/7-1  (537477296)"],"award-info":[{"award-number":["BA 2851\/7-1  (537477296)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Predicting response to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer (NSCLC) remains challenging. Serum metabolomics offers a promising approach to identify biomarkers capturing host\u2013tumor metabolic interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted nuclear magnetic resonance (NMR) spectroscopy-based metabolomic analysis on 216 longitudinal serum samples from 36 patients with advanced NSCLC receiving first-line pembrolizumab plus chemotherapy. We examined how baseline and dynamic metabolite profiles related to survival and impending disease progression, applying multivariate analyses and Random Forest (RF) modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lower serum levels of branched-chain amino acids (BCAAs) valine and isoleucine were associated with disease progression within 60 days. Overall survival was linked to distinct metabolomic signatures: long-term survivors showed higher serum levels of various lipids, including total phospholipids, sphingomyelin, and apolipoproteins A1 and A2. In contrast, patients who died during follow-up had higher inflammatory markers, including glycoprotein acetyls and mannose. An RF model predicted survival status with high accuracy (AUC\u00a0=\u00a00.93), with sphingomyelin, apolipoprotein A2, and glycoprotein acetyls B among the top contributors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum metabolomic profiles are closely linked to clinical outcomes in advanced NSCLC treated with pembrolizumab plus chemotherapy. Key metabolites \u2013 particularly BCAAs, lipids, and inflammatory markers \u2013 emerge as promising non-invasive biomarkers for predicting progression and survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1770764","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:42:42Z","timestamp":1779082962000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Peter","family":"May","sequence":"first","affiliation":[{"name":"Department of Medicine III, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Hubrecht","sequence":"additional","affiliation":[{"name":"Department of Medicine III, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Patenge","sequence":"additional","affiliation":[{"name":"Department of Medicine III, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Strathmeyer","sequence":"additional","affiliation":[{"name":"lifespin GmbH","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Geyer","sequence":"additional","affiliation":[{"name":"lifespin GmbH","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Heelemann","sequence":"additional","affiliation":[{"name":"lifespin GmbH","place":["Regensburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Stratmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Pulmonology, Allergology, Intensive Care Medicine, Saarland University Hospital","place":["Homburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyer","family":"Safi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folker","family":"Schneller","sequence":"additional","affiliation":[{"name":"Department of Medicine III, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich","place":["Munich, Germany"]},{"name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK)","place":["Heidelberg, Germany"]},{"name":"Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Becker von Rose","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, TUM School of Medicine and Health, Technical University of Munich","place":["Munich, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer\u2014epidemiology, pathogenesis, treatment and molecular aspect (review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-839","article-title":"Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer","volume":"10","author":"Duchemann","year":"2020","journal-title":"Trans Lung Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104332","article-title":"Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path","volume":"197","author":"Spagnolo","year":"2024","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184543","article-title":"NSCLC biomarkers to predict response to immunotherapy with checkpoint inhibitors (ICI): From the cells to in vivo images","volume":"13","author":"Liberini","year":"2021","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00044","article-title":"Metabolomics and its application to acute lung diseases","volume":"7","author":"Stringer","year":"2016","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.molmet.2019.08.010","article-title":"Clinical and lifestyle related factors influencing whole blood metabolite levels - a comparative analysis of three large cohorts","volume":"29","author":"Beuchel","year":"2019","journal-title":"Mol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40169-016-0110-9","article-title":"Clinical significance of T cell metabolic reprogramming in cancer","volume":"5","author":"Herbel","year":"2016","journal-title":"Clin Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6484","article-title":"The tryptophan\u2013kynurenine pathway in immunomodulation and cancer metastasis","volume":"12","author":"Basson","year":"2023","journal-title":"Cancer Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12369","article-title":"Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers","volume":"12","author":"Moreno","year":"2018","journal-title":"Mol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumor immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1016\/j.annonc.2023.09.2919","article-title":"196P serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts","volume":"34","author":"Xu","year":"2023","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1545976","article-title":"Metabolomic machine learning-based model predicts efficacy of chemoimmunotherapy for advanced lung squamous cell carcinoma","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15050340","article-title":"Characterizing plasma-based metabolomic signatures for metastasis in non-small cell lung cancer","volume":"15","author":"Liu","year":"2025","journal-title":"Metabolites"},{"key":"B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/metabo9070123","article-title":"NMR spectroscopy for metabolomics research","volume":"9","author":"Emwas","year":"2019","journal-title":"Metabolites"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae704","article-title":"An NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy","volume":"110","author":"Ladurner","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/mco.0000000000000430","article-title":"Branched-chain amino acid metabolism in cancer","volume":"21","author":"Ananieva","year":"2018","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.678753","article-title":"Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer","volume":"8","author":"Nie","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03828","article-title":"Arginine-dependent immune responses","volume":"78","author":"Mart\u00ed","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00864","article-title":"Reconstitution of T cell proliferation under arginine limitation: Activated human T cells take up citrulline via L-type amino acid transporter 1 and use it to regenerate arginine after induction of argininosuccinate synthase expression","volume":"8","author":"Werner","year":"2017","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-010389","article-title":"Suppression of T-cell functions by human granulocyte arginase","volume":"108","author":"Munder","year":"2006","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071926","article-title":"Metabolites as prognostic markers for metastatic non-small cell lung cancer (NSCLC) patients treated with first-line platinum-doublet chemotherapy","volume":"12","author":"Hao","year":"2020","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70223","article-title":"The prognosis and metabolite changes of NSCLC patients receiving first-line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification","volume":"13","author":"Zheng","year":"2024","journal-title":"Cancer Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1548655","article-title":"Investigation of sphingolipid-related genes in lung adenocarcinoma","volume":"12","author":"Mao","year":"2025","journal-title":"Front Mol Biosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.10.005","article-title":"Membranes in balance: Mechanisms of sphingolipid homeostasis","volume":"40","author":"Breslow","year":"2010","journal-title":"Mol Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106850","article-title":"CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer","volume":"194","author":"Wang","year":"2023","journal-title":"Pharmacol Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.3390\/ijms22126492","article-title":"The role of sphingolipids in cancer immunotherapy","volume":"22","author":"Giussani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12944-021-01581-y","article-title":"Cell surface sphingomyelin: Key role in cancer initiation, progression, and immune evasion","volume":"20","author":"Tallima","year":"2021","journal-title":"Lipids Health Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3002-2-18","article-title":"Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia","volume":"2","author":"Shukla","year":"2014","journal-title":"Cancer Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1213952","article-title":"High serum mannose in colorectal cancer: A novel biomarker of lymph node metastasis and poor prognosis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-15964","article-title":"Glycan analysis of serum and breast tissue identifies potential biomarkers of cancer subtype and severity","author":"Kamili","year":"2026","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.255828","article-title":"Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events","volume":"62","author":"Duprez","year":"2016","journal-title":"Clin Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100120","article-title":"GlycA measured by NMR spectroscopy is associated with disease activity and cardiovascular disease risk in chronic inflammatory diseases","volume":"4","author":"Mehta","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01980-3","article-title":"Metabolomic profiles predict individual multidisease outcomes","volume":"28","author":"Buergel","year":"2022","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2014.232918","article-title":"GlycA: A composite nuclear magnetic resonance biomarker of systemic inflammation","volume":"61","author":"Otvos","year":"2015","journal-title":"Clin Chem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12916-025-03993-4","article-title":"Association of circulating metabolic biomarkers with risk of lung cancer: A population-based prospective cohort study","volume":"23","author":"Wu","year":"2025","journal-title":"BMC Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-2855","article-title":"Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling","volume":"24","author":"Tian","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101393","article-title":"Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling","volume":"19","author":"Gong","year":"2022","journal-title":"Transl Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e008190","DOI":"10.1136\/jitc-2023-008190","article-title":"Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer","volume":"12","author":"Zheng","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31110544","article-title":"Sex-related differences in immunotherapy outcomes of patients with advanced non-small cell lung cancer","volume":"31","author":"Cohen","year":"2024","journal-title":"Curr Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-300","article-title":"Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer","volume":"14","author":"May","year":"2025","journal-title":"Trans Lung Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-1201","article-title":"Gut microbiota and metabolites associated with immunotherapy efficacy in extensive-stage small cell lung cancer: A pilot study","volume":"16","author":"Sun","year":"2024","journal-title":"J Thorac Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i20.4091","article-title":"Machine learning based on metabolomics unveils neutrophil extracellular trap-related metabolic signatures in non-small cell lung cancer patients undergoing chemoimmunotherapy","volume":"12","author":"Li","year":"2024","journal-title":"World J Clin cases"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:42:43Z","timestamp":1779082963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1770764"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1770764","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1770764"}}